Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPEDITION-4: Mavyret in Renally-Impaired Adults with Chronic HCV
NCT02651194Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2015
- Primary completion
- Oct 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 3, open-label, single-arm trial of glecaprevir in hepatitis C (HCV), sponsored by AbbVie Inc. Primary endpoint: Sustained Virologic Response 12 Weeks Post-treatment. Started Dec 2015; status: completed.
02
Drugs
glecaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02651194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02651194.